Avalo Therapeutics (AVTX) Equity Average (2015 - 2026)

Avalo Therapeutics (AVTX) has 12 years of Equity Average data on file, last reported at $75.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 40.79% year-over-year to $75.7 million; the trailing twelve-month figure through Mar 2026 stood at $75.7 million (down 40.79% YoY), and the FY2025 full-year result was $108.0 million, up 53.97% from the prior year.
• Equity Average for Q1 2026 stood at $75.7 million, down from $87.3 million in the prior quarter.
• Across five years, Equity Average topped out at $127.8 million in Q1 2025 and bottomed at -$63.1 million in Q2 2024.
• The 5-year median for Equity Average is $3.9 million (2023), against an average of $27.7 million.
• The widest annual swing landed in 2023, when Equity Average sank 3485.17%; it then soared 2526.15% in 2025.
• A 5-year view of Equity Average shows it stood at -$6.5 million in 2022, then jumped by 269.97% to $11.0 million in 2023, then surged by 600.52% to $77.1 million in 2024, then climbed by 13.29% to $87.3 million in 2025, then dropped by 13.3% to $75.7 million in 2026.
• The last three Equity Average figures came in at $75.7 million (Q1 2026), $87.3 million (Q4 2025), and $98.1 million (Q3 2025), per Business Quant data.

Peer Comparison